

NOVA EYE SUCCESSFULLY COMPLETES PLACEMENT AND INSTITUTIONAL ENTITLEMENT OFFER

Highlights

- **Nova Eye completes Placement and Institutional Entitlement Offer of \$5.1 million with a fully underwritten Retail Entitlement Offer for a further \$2.9 million for a total capital raise of \$8 million.**
- **This Placement and Institutional Entitlement Offer raised a total of \$5.1 million with strong support from both existing and new institutional and sophisticated investors.**
- **The fully underwritten Retail Entitlement Offer to raise \$2.9 million will open at 9:00am (Sydney time), Monday, 19 February 2024.**
- **The Placement and Institutional Entitlement Offer structure comprises a \$3.0 million institutional placement and a \$2.1 million Institutional component of the Accelerated Non-Renounceable Entitlement Offer at \$0.21 per share including full participation from the Chair and Managing Director.**
- **The pro-forma cash balance at the completion of the Placement and Entitlement Offer and the Retail Entitlement Offer will be approximately \$10.0 million.**
- **Funds raised will be used to further near-term growth opportunities across Nova Eye's Glaucoma business, including expanding the geographical presence of *iTrack™* Advance sales in the US and Europe, and to broaden the product portfolio of glaucoma surgical devices.**

Nova Eye Medical Limited (ASX: EYE) (**Nova Eye Medical** or the **Company**), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces the successful completion of its Placement (**Placement**) and the institutional component of its fully underwritten 1 for 8.0 accelerated non renounceable entitlement offer (**ANREO** or **Entitlement Offer**) of new fully paid ordinary shares (**New Shares**). The Placement and ANREO (together, the **Offer**) raised approximately \$5.1 million at \$0.21 per New Share (**Offer Price**) and was strongly supported by new and existing institutional and sophisticated Nova Eye shareholders. The Chair and the Managing Director have stated that they will be taking up their full entitlements under the Entitlements Offer.

Settlement of the New Shares issued as part of the Placement and Institutional Entitlement Offer is expected to occur on Wednesday, 21 February 2024, with the issue of those New Shares expected to occur and ordinary trading to commence on Thursday, 22 February 2024.

The New Shares will rank pari passu to existing shares on issue. Nova Eye has requested its trading halt be lifted and for its shares to recommence trading from market open today.

Retail Entitlement Offer

Eligible retail shareholders at the Record Date of 7:00pm (Sydney time) Wednesday, 14 February 2024, with a registered address in Australia, New Zealand, Hong Kong, or Singapore (**Eligible Retail Shareholders**) will be invited to participate in the Retail Entitlement Offer at the Offer Price.

The Retail Entitlement Offer will open on 9:00am (Sydney time) Monday, 19 February 2024 and close at 5:00pm (Sydney time) on Friday, 8 March 2024 (**Retail Entitlement Offer Period**). The Retail Entitlement Offer to raise a further approximately \$2.9 million is fully underwritten.

Further information will be sent to Eligible Retail Shareholders in a booklet (**Retail Offer Booklet**) expected to be lodged with ASX and despatched or otherwise made available on or around Monday, 19 February 2024.

In addition to each Eligible Retail Shareholders' Entitlement under the Retail Entitlement Offer, Eligible Retail Shareholders will be offered the opportunity to apply for additional New Shares under a "top up" facility (**Top Up Facility**). Under the Top Up Facility, Eligible Retail Shareholders who hold up to 10,000 shares at the Record Date and take up their full Entitlement may also apply for New Shares more than their Entitlement at the Offer Price up to a maximum \$5,000. Eligible Retail Shareholders who hold more than 10,000 shares at the Record Date and who take up their full Entitlement may also apply for New Shares more than their Entitlement at the Offer Price up to a value of 50% of their Entitlement.

Eligible Retail Shareholders are not assured of being allocated New Shares in excess of their Entitlement under the Top Up Facility. New Shares allocated under the Top Up Facility will be allocated in accordance with the allocation policy described in the Retail Offer Booklet. The Company retains absolute discretion regarding allocation under the Top Up Facility.

The Retail Offer Booklet and a personalised entitlement and acceptance form (**Application Form**) will contain instructions on how to apply for New Shares as part of the Retail Entitlement Offer.

Application Forms and payments are due by no later than 5:00pm (Sydney time) on Friday, 8 March 2024.

For questions in relation to the Retail Entitlement Offer, please contact the Offer Information Line on 1300 556 161 (within Australia) or +61 3 9415 4000 (outside Australia) any time between 8:30am to 5:30pm (Sydney time), Monday to Friday (excluding public holidays in New South Wales) during the Retail Entitlement Offer Period or visit the Offer Website at www.computersharecas.com.au/novaeyeoffer. For other questions, you should consult your broker, solicitor, accountant, financial adviser, or other professional adviser.

Entitlement offer and Placement Timetable

Announcement of completion of the Institutional Entitlement offer, trading halt lifted, existing securities recommence trading	Wednesday, 14 February 2024
Retail Entitlement Offer opens	Monday, 19 February 2024
Allotment of New Shares issued under the Institutional Entitlement Offer and Placement	Thursday, 22 February 2024
Retail Entitlement Offer closes	Friday, 08 March 2024
Settlement of New Shares under the Retail Entitlement Offer and any shortfall	Thursday, 14 March 2024
Announcement of results of the Retail Entitlement Offer and notification of any shortfall	Friday, 15 March 2024
Allotment and issue of New Shares under the Retail Entitlement Offer	Friday, 15 March 2024
Trading commences on a normal basis for New Shares issued under the Retail Entitlement Offer	Monday, 18 March 2024

The Offer was conducted by Taylor Collison Limited, E&P Corporate Advisory Pty Ltd and MST Financial Services Pty Ltd as joint lead managers.

Authorised for lodgement by the Board of Directors of Nova Eye Medical Limited.

– ENDS –

Company

Tom Spurling
 Managing Director
 +61 417 818 658
tspurling@nova-eye.com

Investors

Mark Flynn
 Investor Relations
 +61 416 068 733
mflynn@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

Zealand.

For additional information about Nova Eye Medical and its technologies, please visit:

www.nova-eye.com